Tesamorelin
Approvedaka Egrifta
Approved GHRH analog, specifically for shifting visceral belly fat.
Mechanism
A stabilised GHRH analog that raises GH and IGF-1. It got approved for one narrow job, cutting the deep visceral fat that builds up in HIV-associated lipodystrophy, and it's good at it.
Regulatory & Safety Status
Approved as Egrifta for HIV-associated lipodystrophy. Prescription drug. Everything else people run it for is off-label.
Research
Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment
Latest tesamorelin research